Leslie J Kohman1, Lin Gu2, Nasser Altorki3, Ernest Scalzetti4, Linda J Veit5, Jason M Wallen5, Xiaofei Wang2. 1. Department of Surgery, State University of New York Upstate Medical University, Syracuse, NY. Electronic address: kohmanl@upstate.edu. 2. Alliance Statistics and Data Center, Duke University Medical Center, Durham, NC. 3. Department of Surgery, Weill Cornell Medicine, New York Presbyterian Hospital, New York, NY. 4. Department of Radiology, State University of New York Upstate Medical University, Syracuse, NY. 5. Department of Surgery, State University of New York Upstate Medical University, Syracuse, NY.
Abstract
OBJECTIVE: Cancer and Leukemia Group B 140503 is an ongoing, multicenter randomized trial assessing whether sublobar resection is equivalent to lobectomy for the treatment of stage I A non-small cell lung cancer (NSCLC) ≤2 cm in diameter. The objective of this report is to determine the reasons precluding intraoperative randomization. METHODS:From June 15, 2007, to March 22, 2013, 637 patients were preregistered to the trial. Three hundred eighty-nine were randomized successfully (61%), and 248 patients were not randomized (39%). We analyzed the reasons for nonrandomization among a subset of the nonrandomized patients (208) for whom additional data were available. RESULTS: Of these 208 patients, undiagnosed benign nodules (n =104, 16% of all registered patients) and understaging of NSCLC (n =45, 7% of all registered patients) were the dominant reasons precluding randomization. Granulomas represent one-quarter of the benign nodules. The understaged patients had unsuspected nodal metastases (n =28) or other more advanced NSCLC. The rate of randomization was significantly greater in those patients who had a preoperative biopsy (P <.001). CONCLUSIONS: In a carefully monitored cohort of patients with suspected small NSCLC ≤2 cm, a substantial number are misdiagnosed (benign nodules) or understaged. These patients may not have benefited from a thoracic surgical procedure. Preoperative biopsy significantly increased the rate of correct diagnosis. Preoperative biopsy of small suspected NSCLC will reduce the number of nontherapeutic or unnecessary thoracic procedures. Accuracy in preoperative diagnosis is increasingly important as more such small nodules are discovered through lung cancer screening.
RCT Entities:
OBJECTIVE:Cancer and Leukemia Group B 140503 is an ongoing, multicenter randomized trial assessing whether sublobar resection is equivalent to lobectomy for the treatment of stage I A non-small cell lung cancer (NSCLC) ≤2 cm in diameter. The objective of this report is to determine the reasons precluding intraoperative randomization. METHODS: From June 15, 2007, to March 22, 2013, 637 patients were preregistered to the trial. Three hundred eighty-nine were randomized successfully (61%), and 248 patients were not randomized (39%). We analyzed the reasons for nonrandomization among a subset of the nonrandomized patients (208) for whom additional data were available. RESULTS: Of these 208 patients, undiagnosed benign nodules (n =104, 16% of all registered patients) and understaging of NSCLC (n =45, 7% of all registered patients) were the dominant reasons precluding randomization. Granulomas represent one-quarter of the benign nodules. The understaged patients had unsuspected nodal metastases (n =28) or other more advanced NSCLC. The rate of randomization was significantly greater in those patients who had a preoperative biopsy (P <.001). CONCLUSIONS: In a carefully monitored cohort of patients with suspected small NSCLC ≤2 cm, a substantial number are misdiagnosed (benign nodules) or understaged. These patients may not have benefited from a thoracic surgical procedure. Preoperative biopsy significantly increased the rate of correct diagnosis. Preoperative biopsy of small suspected NSCLC will reduce the number of nontherapeutic or unnecessary thoracic procedures. Accuracy in preoperative diagnosis is increasingly important as more such small nodules are discovered through lung cancer screening.
Authors: Brendon M Stiles; Michael Schulster; Abu Nasar; Subroto Paul; Paul C Lee; Jeffrey L Port; Nasser K Altorki Journal: J Thorac Cardiovasc Surg Date: 2014-10-14 Impact factor: 5.209
Authors: C I Henschke; D I McCauley; D F Yankelevitz; D P Naidich; G McGuinness; O S Miettinen; D M Libby; M W Pasmantier; J Koizumi; N K Altorki; J P Smith Journal: Lancet Date: 1999-07-10 Impact factor: 79.321
Authors: G Veronesi; P Maisonneuve; C Rampinelli; R Bertolotti; F Petrella; L Spaggiari; M Bellomi Journal: Lung Cancer Date: 2013-09-08 Impact factor: 5.705
Authors: Daniel J Boffa; Andrzej S Kosinski; Subroto Paul; John D Mitchell; Mark Onaitis Journal: Ann Thorac Surg Date: 2012-06-27 Impact factor: 4.330
Authors: Joshua R Niska; Terence T Sio; Thomas B Daniels; Staci E Beamer; Dawn E Jaroszewski; Helen J Ross; Harshita R Paripati; Steven E Schild Journal: J Thorac Dis Date: 2018-06 Impact factor: 2.895
Authors: Christopher Cao; David H Tian; Daniel R Wang; Caroline D Chung; Dominique Gossot; Matthew Bott Journal: J Thorac Dis Date: 2017-12 Impact factor: 2.895
Authors: Nasser K Altorki; Xiaofei Wang; Dennis Wigle; Lin Gu; Gail Darling; Ahmad S Ashrafi; Rodney Landrenau; Daniel Miller; Moishe Liberman; David R Jones; Robert Keenan; Massimo Conti; Gavin Wright; Linda J Veit; Suresh S Ramalingam; Mohamed Kamel; Harvey I Pass; John D Mitchell; Thomas Stinchcombe; Everett Vokes; Leslie J Kohman Journal: Lancet Respir Med Date: 2018-11-12 Impact factor: 30.700
Authors: Waseem Lutfi; Matthew J Schuchert; Rajeev Dhupar; Chigozirim Ekeke; Inderpal S Sarkaria; Neil A Christie; James D Luketich; Olugbenga T Okusanya Journal: Clin Lung Cancer Date: 2019-04-01 Impact factor: 4.785